Avutometinib: A Comprehensive Review of a Novel RAF/MEK Inhibitor in Oncology

I. Introduction to Avutometinib

A. Overview of Avutometinib as an Investigational Agent

Avutometinib, also identified by its developmental codes RO-5126766 (free base), VS-6766, and CH5126766, is an orally bioavailable small molecule inhibitor currently under extensive clinical investigation for a variety of oncological indications.[1] It has been distinguished as a "first-in-class" dual inhibitor of Raf and MEK (mitogen-activated protein kinase kinase), representing a novel therapeutic strategy within its category.[2] The agent's development has included evaluation in clinical trials such as NCT03875820, a Phase 1 study assessing the combination of VS-6063 (defactinib) and RO5126766 (avutometinib), which serves as a notable point in its clinical journey.

B. Therapeutic Rationale in RAS/MAPK Pathway-Driven Cancers

The therapeutic rationale for avutometinib is rooted in its ability to target and inhibit the Raf/MEK-mediated signal transduction pathways. These pathways are fundamental to regulating cellular processes such as gene expression, mitosis, differentiation, and apoptosis, and their dysregulation is a common hallmark of cancer, contributing significantly to tumor cell proliferation and survival.[1] The RAS/MAPK (Rat Sarcoma virus/Mitogen-Activated Protein Kinase) pathway is frequently activated aberrantly in numerous human cancers due to mutations in key oncogenes like KRAS, NRAS, or BRAF.[5] Avutometinib's mechanism of action is specifically designed to counteract the effects of this dysregulated signaling. Preclinical studies have demonstrated its efficacy in cancer cell lines harboring RAS mutations and in corresponding xenograft models, providing a solid foundation for its clinical development in genetically defined patient populations.[2]

The extensive involvement of the RAS/MAPK pathway across a multitude of cancer types suggests that avutometinib may possess a broad spectrum of potential applicability, extending beyond any single initial approved indication. The RAS/MAPK cascade is a critical signaling network that governs essential cellular functions, including growth and survival. Oncogenic mutations in components of this pathway, such as KRAS and BRAF, are prevalent across diverse malignancies. Given that avutometinib targets RAF and MEK, crucial nodes within this pathway, its effective inhibition could translate into therapeutic benefits for various cancers characterized by these specific molecular alterations. This potential for broad utility is supported by the diverse portfolio of clinical trials investigating avutometinib in conditions such as low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, melanoma, and colorectal cancer, among others.[8]

Furthermore, the development trajectory of avutometinib aligns with the broader paradigm shift in oncology towards personalized medicine. This approach emphasizes tailoring treatments based on the specific molecular characteristics of an individual patient's tumor. The clinical development of avutometinib has consistently highlighted the importance of KRAS mutation status, often as a key inclusion criterion for trials or as a significant factor influencing treatment efficacy.[10] Notably, the U.S. Food and Drug Administration (FDA) approval for avutometinib in combination with defactinib for LGSOC is specifically for patients whose tumors harbor KRAS mutations.[12] Ongoing biomarker research, such as investigations into the relevance of epithelial-mesenchymal transition (EMT) status in KRAS-mutated NSCLC [14], further underscores the commitment to identifying patient subgroups most likely to derive benefit from this targeted therapy. Such a precision-guided strategy aims to maximize therapeutic efficacy while concurrently minimizing the potential for unnecessary toxicity, a cornerstone of modern personalized oncology.

II. Drug Profile and Physicochemical Characteristics

A. Nomenclature and Identifiers

Avutometinib is the International Nonproprietary Name (INN) and United States Adopted Name (USAN) for this small molecule drug.[1] Key identifiers include:

• DrugBank ID: DB15254 [1]
• CAS Number: 946128-88-7 [1]
• Type: Small Molecule [1]
• Synonyms and Developmental Codes: RO-5126766 (free base), CH5126766, VS-6766, RG 7304, CKI-27, R-7304. A comprehensive list of synonyms can be found in various chemical databases.[1] These multiple identifiers reflect its progression through various research and development stages and sponsorship by different entities.

B. Chemical Structure and Molecular Formula

The chemical identity of avutometinib is defined by the following:

• Molecular Formula: C21​H18​FN5​O5​S [1]
• IUPAC Name: 3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one.[1]
• Structural Classification: It is described as a member of the coumarin class of compounds, and also possesses structural features of an aryloxypyrimidine, a pyridine, an organofluorine compound, and a sulfamide.[1]
• InChI Key: LMMJFBMMJUMSJS-UHFFFAOYSA-N [2]
• Canonical SMILES: CNS(=O)(=O)Nc1nccc(c1F)Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1 [3]

These structural details are fundamental for chemists, pharmacologists, and regulatory authorities, and its classification as a coumarin derivative provides a basis for understanding some of its physicochemical behaviors.

C. Key Physicochemical Properties

Avutometinib exhibits several key physicochemical properties relevant to its pharmaceutical development and biological activity:

• Molecular Weight: Reported values are approximately 471.46 to 471.5 g/mol. Specific computed values include 471.10126803 Da (monoisotopic) and 471.5 g/mol from PubChem [1], 471.460 g/mol from MedKoo Biosciences [2], and 471.47 g/mol from ChEMBL.[15] These slight variations are typical and may arise from different computational methods or isotopic considerations.
• Solubility: Avutometinib is reported to be soluble in dimethyl sulfoxide (DMSO), with specific values cited as >25 mg/mL [5] and 125 mg/mL.[2] It is not soluble in water.[2] This solubility profile is critical for its formulation, particularly for oral administration, and for its use in in vitro experimental setups where DMSO is a common solvent.
• Stability and Storage: The compound is shipped under ambient temperature conditions and is considered stable for several weeks during ordinary shipping and customs processing. For storage, it is recommended to keep it dry, protected from light, and at 0-4 °C for short-term periods (days to weeks) or at -20 °C for long-term storage (months to years). Solutions prepared in DMSO may be stored at -20 °C for up to 3 months.[2] The shelf life is stated as greater than 2 years if stored properly.[2] These stability characteristics are essential for maintaining the integrity of the compound for research and potential pharmaceutical product formulation.
• Other Computed Properties: Several other properties, often used to predict drug-likeness and pharmacokinetic behavior, have been computed:
• Hydrogen Bond Acceptors: 7 [3] or 8 (Lipinski: 10) [15]
• Hydrogen Bond Donors: 2 [3]
• Rotatable Bonds: 7 [3]
• Topological Polar Surface Area (TPSA): 144.69 A˚2 [3] or 136.31 A˚2 [15]
• XLogP / AlogP (octanol-water partition coefficient): 2.96 [3] or 2.68 [15]
• Lipinski's Rule of 5 Violations: 0 [3] Adherence to Lipinski's rules, indicated by zero violations, suggests a favorable profile for oral bioavailability and drug-like characteristics.

A summary of these core identifiers and properties is provided in Table II.1.

Table II.1: Key Identifiers and Physicochemical Properties of Avutometinib

Property	Value	Source Document(s)
DrugBank ID	DB15254	User Query, 1
CAS Number	946128-88-7	User Query, 1
Molecular Formula	C21​H18​FN5​O5​S	1
Molecular Weight (Average)	~471.46 - 471.5 g/mol	1
IUPAC Name	3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one	1
Key Synonyms	VS-6766, RO-5126766, CH5126766	1
Solubility (DMSO)	Soluble (e.g., >25 mg/mL, 125 mg/mL)	2
Solubility (Water)	Not soluble	2
Storage Conditions	Dry, dark; 0-4 °C (short term) or -20 °C (long term)	2
XLogP / AlogP	2.96 / 2.68	3
Lipinski's Rule of 5 Violations	0	3

III. Pharmacology and Mechanism of Action

A. Classification: Dual RAF/MEK Inhibitor

Avutometinib is classified as an orally bioavailable inhibitor that targets the serine/threonine protein kinases Raf and mitogen-activated protein kinase kinase (MAP2K), commonly known as MAPK/ERK kinase or MEK.[1] It is notably described as a "first-in-class" dual RAF/MEK inhibitor.[2] This dual-targeting capability distinguishes it from other kinase inhibitors that may selectively target only MEK or only Raf, forming the basis of its unique pharmacological profile and potential therapeutic advantages in overcoming certain resistance mechanisms.

B. Detailed Mechanism: Allosteric Inhibition, Impact on MEK Phosphorylation and RAF/MEK Complex

Avutometinib exerts its anticancer effects by specifically binding to and inhibiting the kinase activities of both Raf and MEK proteins within the RAS/MAPK signaling cascade.[1] Its mechanism of action is particularly unique and has been termed a "RAF/MEK clamp".[5]

Key features of this mechanism include:

1. Direct Inhibition of Unphosphorylated MEK: Avutometinib directly inhibits MEK in its unphosphorylated state. Crucially, this inhibition occurs without inducing the compensatory phosphorylation of MEK by Raf. Such feedback phosphorylation is a common adaptive resistance mechanism observed with many other MEK inhibitors, where initial MEK inhibition leads to relief of ERK-dependent negative feedback on Raf, causing Raf to hyperactivate and phosphorylate more MEK, thereby attenuating the inhibitory effect.[5]
2. Formation of a Dominant-Negative RAF/MEK Complex: The binding of avutometinib to MEK creates an adduct that functions as a dominant-negative inhibitor of Raf. This avutometinib-MEK complex stabilizes the interaction between MEK and Raf, locking this complex in an inactive conformation.[5]
3. Prevention of Compensatory MEK Activation: By trapping MEK with Raf in an inactive state, avutometinib effectively blocks MEK signaling without the paradoxical compensatory activation of MEK often seen with other inhibitors in this class. This allows for a more complete and sustained inhibition of ERK signaling downstream.[9]

The net result of this "RAF/MEK clamp" mechanism is a profound inhibition of the Raf/MEK-mediated signal transduction pathways. This, in turn, leads to the suppression of Raf/MEK-dependent tumor cell proliferation and a reduction in tumor cell survival.[1]

This innovative "RAF/MEK clamp" mechanism represents a significant pharmacological advancement designed to circumvent the adaptive resistance frequently encountered with single-agent MEK inhibitors. Standard MEK inhibitors, by targeting MEK alone, can inadvertently trigger a feedback loop that reactivates Raf. This reactivated Raf then phosphorylates additional MEK molecules, thereby limiting the depth and duration of pathway inhibition.[5] Avutometinib's dual action—directly inhibiting MEK while simultaneously preventing Raf-mediated MEK phosphorylation through the formation of an inactive RAF/MEK complex—effectively addresses this critical feedback loop.[5] Consequently, avutometinib may offer more sustained and profound pathway inhibition. This characteristic suggests its potential utility in tumors that have developed resistance to other MEK inhibitors or in contexts where this feedback reactivation pathway is particularly active. Indeed, preclinical data indicate activity in settings where tumors have previously progressed on other MEK inhibitors, supporting this hypothesis.[9]

C. Molecular Targets and Binding Affinity (IC50 values)

Avutometinib functions as an allosteric inhibitor, demonstrating potent activity against several key kinases in the MAPK pathway. The reported half-maximal inhibitory concentrations (IC50 values) are:

• BRAF V600E: 8 nM [5] or 8.2 nM [2]
• BRAF (wild-type): 19 nM [5] (Note: one source [2] reports 190 nM for BRAF, but 19 nM appears more consistent with other reported potencies and is cited in a source detailing multiple IC50s [5]).
• CRAF: 56 nM [2]
• MEK (presumably MEK1 and/or MEK2): 160 nM [2]

Furthermore, avutometinib is documented to inhibit Dual specificity mitogen-activated protein kinase kinase 1 (MEK1, Target ChEMBL ID: CHEMBL3587) and Dual specificity mitogen-activated protein kinase kinase 2 (MEK2, Target ChEMBL ID: CHEMBL2964).[15] These nanomolar IC50 values signify high binding affinity and potent inhibition of its molecular targets. The activity against both mutant (V600E) and wild-type BRAF, in addition to CRAF and MEK, underscores its comprehensive dual-targeting nature within the pathway.

The observed potency of avutometinib against not only the common BRAF V600E mutant (IC50 ~8 nM) but also against wild-type BRAF (IC50 ~19 nM), CRAF (IC50 ~56 nM), and MEK (IC50 ~160 nM) is noteworthy.[5] This broad inhibitory profile suggests that its therapeutic utility is not confined to cancers driven by BRAF mutations. Instead, it can extend to malignancies harboring other alterations in the RAS/MAPK pathway, such as KRAS or NRAS mutations, where wild-type RAF isoforms (BRAF and CRAF) and MEK act as critical downstream effectors. Mutations in KRAS or NRAS lead to the activation of these wild-type RAF proteins, which then signal through MEK. By effectively inhibiting these downstream components, avutometinib can block aberrant signaling irrespective of whether BRAF itself is mutated. This broad applicability is consistent with its demonstrated efficacy in KRAS-mutant LGSOC and NSCLC in clinical settings.[11]

D. Preclinical Evidence of Anti-Tumor Activity

Preclinical investigations have provided substantial evidence supporting the anti-tumor activity of avutometinib. It has been identified as an effective RAF/MEK inhibitor in various RAS-mutated malignant tumor models, including melanoma.[2] In vitro studies demonstrated that avutometinib induced G1 cell cycle arrest in melanoma cell lines harboring either BRAF V600E or NRAS mutations.[2] A key finding in RAS-mutated cells was its ability to suppress the MEK reactivation that is often induced by other, more selective MEK inhibitors.[2]

Avutometinib has shown efficacy across a panel of RAS-mutated cancer cell lines and has demonstrated tumor growth suppression in vivo in an SK-MEL-2 melanoma xenograft model, which harbors an NRAS mutation.[2]

Furthermore, synergistic anti-tumor effects have been observed when avutometinib is combined with other anticancer agents:

• With eribulin, against triple-negative breast cancer cell lines.[5]
• With the FAK (Focal Adhesion Kinase) inhibitor defactinib, in KRAS-mutated NSCLC cells.[5]
• With KRAS G12C inhibitors, showing enhanced cancer cell viability reduction and tumor regression in KRAS G12C mutant NSCLC and colorectal cancer (CRC) cell lines and mouse models.[16]

These preclinical data have been instrumental in establishing the proof-of-concept for avutometinib's mechanism and its anti-neoplastic effects, and have played a crucial role in identifying promising combination strategies for clinical development.

The preclinical demonstration of synergy between avutometinib and FAK inhibitors, such as defactinib, offers a compelling scientific basis for the combination strategy that has subsequently shown notable clinical success, particularly in LGSOC and KRAS-mutated NSCLC. Preclinical studies highlighted this synergy in KRAS-mutated NSCLC cells.[5] More specifically, one investigation identified that FAK phosphorylation and activation occur as a feedback or adaptive response following avutometinib treatment in these cells.[14] Therefore, the rationale for combining avutometinib with a FAK inhibitor like defactinib is to preemptively block this adaptive resistance pathway, thereby leading to enhanced and more durable anti-tumor activity. This preclinical hypothesis has been directly translated into the design of clinical trials such as RAMP 201 and FRAME. In these trials, the avutometinib plus defactinib combination has demonstrated significant efficacy, especially in KRAS-mutant LGSOC [11], culminating in an accelerated FDA approval for this indication.[12]

IV. Clinical Development Program of Avutometinib

A. Overview of Clinical Trials Landscape

Avutometinib is undergoing a broad and multifaceted clinical development program, being evaluated both as a monotherapy and, more frequently, in combination with other therapeutic agents across a diverse range of cancer types.[8] Key combination partners in these investigations include the FAK inhibitor defactinib, specific KRAS G12C inhibitors such as sotorasib and adagrasib, standard chemotherapy regimens (e.g., gemcitabine and nab-paclitaxel), and endocrine therapies like letrozole and fulvestrant.[8]

The spectrum of indications being explored is extensive, reflecting the widespread role of the RAS/MAPK pathway in oncogenesis. These include LGSOC, NSCLC (particularly KRAS-mutant subtypes), pancreatic cancer, thyroid cancer, gynecologic mesonephric cancer, melanoma, colorectal cancer, breast cancer, and various pediatric solid tumors.[8] This comprehensive clinical evaluation underscores the significant therapeutic potential envisioned for avutometinib. A summary of key clinical trials is presented in Table IV.1.

Table IV.1: Summary of Key Clinical Trials for Avutometinib

NCT ID	Trial Name/Acronym (if available)	Phase	Indication(s)	Key Intervention(s) (Avutometinib +/- Combination Agents)	Status (as per snippets)	Key Source Document(s) for Reference
NCT03875820	FRAME	1/2	LGSOC, KRASmt NSCLC, CRC, Pancreatic Cancer, KRASmt Endometrial Cancer	Avutometinib + Defactinib	Ongoing, data presented	12
NCT04625270	RAMP 201 (ENGOT-ov60/GOG-3052)	2	Recurrent LGSOC (KRAS-mutant and KRAS WT)	Avutometinib + Defactinib; Avutometinib monotherapy (Part A)	Data presented, supported FDA approval	11
NCT05375994	RAMP 204	1/2	KRAS G12C NSCLC	Avutometinib + Adagrasib	Active Not Recruiting	9
NCT05074810	RAMP 203	1/2	KRAS G12C NSCLC	Avutometinib + Sotorasib	Active	9
N/A	RAMP 205	1b/2	First-line Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)	Avutometinib + Defactinib + Gemcitabine/Nab-paclitaxel	Ongoing, ASCO 2025 update expected	9
N/A	RAMP 202	N/A	NSCLC (BRAF mt)	Avutometinib + Defactinib	Selection Phase (Top-Line Data expected)	9
Various	N/A	Various	Thyroid Cancer, Gynecologic Mesonephric Cancer, Melanoma (brain mets), CRC, Breast Cancer, Pediatric Tumors	Avutometinib + Defactinib (varied combos with other agents like encorafenib, cetuximab, abemaciclib)	Active (various statuses)	8

(Note: "N/A" for Trial Name/Acronym or NCT ID indicates the information was not explicitly provided as such in the available documents, but the trial context was described. Status reflects information at the time of the source documents.)

B. Focus on Low-Grade Serous Ovarian Cancer (LGSOC)

LGSOC is a rare and distinct subtype of ovarian cancer, often characterized by alterations in the RAS/MAPK pathway, including KRAS mutations.[18] Avutometinib, particularly when used in combination with the FAK inhibitor defactinib, has demonstrated significant clinical promise in this patient population, addressing a critical unmet medical need.[11]

1. The RAMP 201 Trial (NCT04625270): Avutometinib in Combination with Defactinib

The RAMP 201 (also known as ENGOT-ov60/GOG-3052) trial is a pivotal, randomized, open-label, multicenter, phase 2 study that has been central to the development of avutometinib in LGSOC.11

• Design: The trial was structured in multiple parts. Part A aimed to determine the optimal therapeutic regimen by comparing avutometinib plus defactinib against avutometinib monotherapy. Subsequent parts (B and C) were designed to further evaluate the efficacy of the selected combination regimen.[11] The established combination dose was avutometinib 3.2 mg orally twice weekly and defactinib 200 mg orally twice daily, both administered for the first 3 weeks of each 4-week cycle.[12]
• Patient Population: Eligible participants were adult patients with recurrent LGSOC who had measurable disease according to RECIST v1.1 criteria, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had received at least one prior line of systemic therapy, which must have included a platinum-based regimen.[11] KRAS mutation status was determined by prospective local testing of tumor tissue.[13]
• Efficacy in KRAS-Mutant LGSOC: This subgroup has shown the most robust response to the combination therapy. Based on data from 57 patients with KRAS-mutated LGSOC:
• Overall Response Rate (ORR) by Blinded Independent Central Review (BICR): 44% (95% Confidence Interval [CI]: 31%-58%).[11] This rate is consistently reported across multiple sources.[19]
• Duration of Response (DOR): The range of DOR was reported as 3.3 months to 31.1 months.[13] The median DOR was 31.1 months (95% CI: 14.8-31.1 months).[11]
• Median Progression-Free Survival (PFS): 22.0 months (95% CI: 11.1-36.6 months).[11]
• Disease Control Rate (DCR) at 6 months: 70%.[11]
• Efficacy in KRAS Wild-Type LGSOC: In patients with KRAS wild-type LGSOC (n=52):
• ORR (BICR): 17% (95% CI: 8%-30%).[11]
• Median DOR: 9.2 months (95% CI: 5.5-not estimated [NE]).[11]
• Median PFS: 12.8 months (95% CI: 7.4-18.4 months).[11]
• DCR (6-month): 50%.[11]
• Efficacy in All Evaluable Patients (n=109):
• ORR (BICR): 31% (95% CI: 23%-41%).[11]
• Median DOR: 31.1 months (95% CI: 14.8-31.1 months).[11]
• Median PFS: 12.9 months (95% CI: 10.9-20.2 months).[11]
• Safety: The combination was generally well-tolerated. Approximately 10% of patients discontinued treatment due to adverse events (AEs). The most common treatment-related AEs (TRAEs) included nausea, diarrhea, and increased blood creatine phosphokinase (CPK) levels.[11] A more detailed safety profile is discussed in Section V. The positive results from RAMP 201, particularly the substantial benefit observed in the KRAS-mutant cohort, formed the primary basis for the FDA's accelerated approval of the avutometinib-defactinib combination.

2. The FRAME Study (NCT03875820): Avutometinib in Combination with Defactinib

The FRAME study was an investigator-initiated Phase 1/2 clinical trial that provided early, crucial data on the combination of avutometinib and defactinib.16

• Design and Significance: This study was the first to evaluate this specific combination in patients with recurrent LGSOC, among other tumor types.[12]
• Efficacy in Recurrent LGSOC: In a cohort of 26 patients with recurrent LGSOC treated with the combination [17]:
• ORR: 42% (11 out of 26 patients).[17] Another report mentioned a 56% ORR in a KRAS-G12 mutant LGSOC cohort from the FRAME study [16]; the 42% figure from a 2024 SGO presentation [17] may represent a more mature or differently defined dataset.
• Median DOR (mDOR): 26.9 months (95% CI: 8.5-47.3 months).[17]
• Median PFS (mPFS): 20.0 months (95% CI: 11.1-31.2 months).[17] The promising results from the FRAME study were instrumental in securing FDA Breakthrough Therapy Designation for the avutometinib and defactinib combination in recurrent LGSOC.[4] Furthermore, these findings provided a strong rationale for proceeding with the larger, registration-directed RAMP 201 trial.[17]

3. Avutometinib Monotherapy in LGSOC (Insights from RAMP 201 Part A)

Part A of the RAMP 201 trial included an initial randomization where patients were assigned to receive either avutometinib monotherapy (at a higher dose of 4.0 mg twice weekly 18) or the combination of avutometinib and defactinib.11 The findings from this direct comparison indicated that the combination regimen achieved a higher response rate and demonstrated similar tolerability when compared to avutometinib administered as a single agent.21 This observation was critical in the decision to advance the combination regimen for further development in Parts B and C of the RAMP 201 study. While specific quantitative efficacy data (ORR, DOR, PFS) for the monotherapy arm from Part A are not extensively detailed in the provided documents, the qualitative superiority of the combination was evident. It is also noteworthy that avutometinib monotherapy, along with the combination, received orphan drug designation for LGSOC from the FDA 19, acknowledging the potential of the single agent in this rare disease.

Table IV.B.1: Efficacy of Avutometinib-Based Regimens in LGSOC (RAMP 201 & FRAME)

Trial (Part/Cohort)	Patient Group (LGSOC)	Treatment Regimen	N	ORR (%)	Median DOR (months)	Median PFS (months)	Source Document(s)
RAMP 201	KRAS-Mutant	Avutometinib + Defactinib	57	44 (95% CI: 31-58)	31.1 (95% CI: 14.8-31.1)	22.0 (95% CI: 11.1-36.6)	11
RAMP 201	KRAS Wild-Type	Avutometinib + Defactinib	52	17 (95% CI: 8-30)	9.2 (95% CI: 5.5-NE)	12.8 (95% CI: 7.4-18.4)	11
RAMP 201	All Evaluable	Avutometinib + Defactinib	109	31 (95% CI: 23-41)	31.1 (95% CI: 14.8-31.1)	12.9 (95% CI: 10.9-20.2)	11
FRAME	Recurrent LGSOC	Avutometinib + Defactinib	26	42	26.9 (95% CI: 8.5-47.3)	20.0 (95% CI: 11.1-31.2)	17
RAMP 201 (Part A Comparison)	Recurrent LGSOC	Avutometinib Monotherapy	N/A	Lower than combo	N/A	N/A	21

(NE = Not Estimated; N/A = Not Available in detail from provided documents)

The markedly superior outcomes observed in patients with KRAS-mutant LGSOC when treated with the avutometinib plus defactinib combination, as compared to those with KRAS wild-type disease, strongly affirm the role of KRAS mutation as a predictive biomarker for this therapeutic regimen in this specific cancer. Data from the RAMP 201 trial consistently show this disparity: an ORR of 44% in the KRAS-mutant group versus 17% in the KRAS wild-type group; a median PFS of 22.0 months versus 12.8 months; and a median DOR of 31.1 months versus 9.2 months, respectively.[11] This substantial difference across multiple key efficacy endpoints strongly suggests that the presence of a KRAS mutation sensitizes LGSOC tumors to this combination therapy. This finding was pivotal for patient selection in clinical trials and formed the rationale for the FDA's targeted approval of the combination specifically for KRAS-mutated LGSOC.

Furthermore, the strategic decision to advance avutometinib in combination with defactinib, rather than as a monotherapy for LGSOC, was directly informed by the results from Part A of the RAMP 201 trial. This part of the study demonstrated that the combination yielded a higher response rate while maintaining a similar tolerability profile compared to avutometinib alone.[21] This clinical observation is consistent with preclinical findings which suggested that FAK activation could serve as a feedback mechanism contributing to resistance against RAF/MEK inhibition.[5] The clinical data from RAMP 201 Part A therefore provide compelling evidence that concurrently inhibiting this FAK-mediated adaptive resistance pathway with defactinib significantly enhances the therapeutic efficacy of avutometinib in the clinical setting of LGSOC.

C. Investigations in Non-Small Cell Lung Cancer (NSCLC)

Avutometinib is also under active investigation in NSCLC, a heterogeneous disease where KRAS mutations are common oncogenic drivers. The focus is predominantly on combination strategies.

• Combination with Defactinib in KRAS-mutant NSCLC: Preclinical studies have indicated synergistic activity between avutometinib and defactinib in this setting.[5] A notable clinical study by Ono et al. (2024) found that treatment with avutometinib led to increased FAK phosphorylation and activation in KRAS-mutated NSCLC cells. Importantly, synergistic effects with defactinib were observed, particularly in cells exhibiting an epithelial phenotype rather than a mesenchymal one.[14] This research suggests that the Epithelial-Mesenchymal Transition (EMT) status of the tumor could serve as a promising biomarker to predict the efficacy of this combination therapy in KRAS-mutated NSCLC.[5]
• Combination with KRAS G12C Inhibitors: Given the advent of specific inhibitors for the KRAS G12C mutation, combining avutometinib with these agents is a rational approach to deepen and prolong pathway inhibition.
• Avutometinib + Adagrasib: The RAMP 204 trial (NCT05375994) is evaluating this combination in patients with KRAS G12C-mutant NSCLC. The trial is listed as active but not currently recruiting.[9]
• Avutometinib + Sotorasib: The RAMP 203 trial (NCT05074810) is a Phase 1/2 study assessing this combination in KRAS G12C-mutant NSCLC.[9] This combination has received Fast Track Designation from the FDA.[23] Preclinical data have demonstrated synergy and even tumor regression when VS-6766 (avutometinib) was combined with KRAS G12C inhibitors (and in some experiments, also with a FAK inhibitor) in relevant models.[16]
• Other NSCLC Contexts: Avutometinib is also being explored in other NSCLC settings, such as in combination with nivolumab (an anti-PD-1 antibody) and defactinib for patients with anti-PD-1 refractory, LKB1-mutant advanced NSCLC.[8] Another Phase 1/2 study is evaluating avutometinib plus sotorasib with or without defactinib in KRAS G12C NSCLC patients.[8] While the FRAME study (NCT03875820) included an NSCLC cohort, and an observation of higher response rates in KRAS-G12V NSCLC was noted [16], detailed results for this specific cohort from FRAME are not extensively covered in the provided information.

The exploration of avutometinib in conjunction with KRAS G12C-specific inhibitors like sotorasib and adagrasib points to a sophisticated strategy aimed at achieving a more profound and durable inhibition of the MAPK pathway. While KRAS G12C inhibitors have shown initial promise, acquired resistance remains a significant challenge.[24] Avutometinib, with its unique "RAF/MEK clamp" mechanism, offers the potential for more complete inhibition of ERK signaling compared to traditional MEK inhibitors.[9] Preclinical evidence supports synergistic effects when avutometinib is combined with G12C inhibitors.[16] By concurrently targeting the KRAS protein directly with a specific inhibitor and blocking downstream signaling at the RAF/MEK nodes with avutometinib, this "double blockade" approach may effectively prevent or delay the emergence of resistance mechanisms that often rely on pathway reactivation or signaling through alternative routes. The RAMP 203 and RAMP 204 clinical trials are designed to test this hypothesis in patients with KRAS G12C-mutant NSCLC.[9]

D. Application in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is another malignancy where RAS pathway mutations, particularly KRAS, are highly prevalent and contribute to its aggressive nature and poor prognosis.

• RAMP 205 Trial: This Phase 1b/2 clinical trial is evaluating avutometinib and defactinib in combination with the standard first-line chemotherapy regimen of gemcitabine and nab-paclitaxel for patients with metastatic PDAC.[25] Updates on safety and efficacy from this trial are anticipated at the ASCO 2025 Annual Meeting, with an abstract (e16043) accepted for publication in the meeting proceedings.[25]
• Preclinical Rationale: The combination strategy is supported by preclinical findings where concomitant inhibition of FAK and RAF-MEK (using avutometinib) led to tumor growth inhibition and increased survival in mouse models of PDAC. This combination also appeared to improve antitumor immunity when administered with chemotherapy.[26]
• The FRAME study (NCT03875820) was also expanded to include a cohort for patients with pancreatic cancer, further indicating interest in this challenging disease.[16]

The combination strategy being investigated in pancreatic cancer—comprising avutometinib, defactinib, and standard chemotherapy—represents a multi-pronged therapeutic attack. This approach aims to target the tumor cells directly through RAF/MEK inhibition by avutometinib and the cytotoxic effects of chemotherapy, while simultaneously modulating the tumor microenvironment through FAK inhibition by defactinib. PDAC is notoriously characterized by a dense, desmoplastic stroma and an immunosuppressive microenvironment, both of which are significant contributors to treatment resistance.[26] FAK inhibitors like defactinib have the potential to disrupt this supportive stroma and alter the immune contexture of the tumor. Avutometinib addresses the frequently mutated KRAS-MAPK pathway within the cancer cells themselves, while gemcitabine and nab-paclitaxel form a standard cytotoxic backbone. Preclinical data lend support to this comprehensive strategy, indicating that combined FAK and RAF-MEK inhibition can enhance antitumor immunity and improve T-cell priming in response to chemotherapy.[26] The RAMP 205 trial is designed to clinically validate this integrated approach.[25]

E. Exploration in Other Malignancies (Brief Overview)

The therapeutic hypothesis for avutometinib—that its mechanism could be beneficial in any tumor driven by MAPK pathway alterations—has led to its investigation in a wide array of other cancers:

• Thyroid Cancer: A study is evaluating avutometinib in combination with defactinib.[8]
• Gynecologic Mesonephric or Mesonephric-Like Cancer: Avutometinib is being studied with defactinib in these rare gynecologic tumors, with a Phase 2 trial mentioned.[8]
• Melanoma: For patients with brain metastases from cutaneous melanoma, a trial is assessing defactinib and avutometinib, with or without encorafenib (a BRAF inhibitor).[8] Preclinical efficacy was observed in the SK-MEL-2 xenograft model [2], and FAK inhibition combined with avutometinib has shown potential to overcome resistance in BRAF V600E melanoma models.[26]
• Colorectal Cancer (CRC):
• A trial is investigating avutometinib, defactinib, and cetuximab (an anti-EGFR antibody) for unresectable or metastatic, refractory CRC.[8]
• Another study is looking at avutometinib and cetuximab for metastatic KRAS-mutated CRC.[8]
• The FRAME study also included a cohort for CRC patients.[16]
• Breast Cancer: For metastatic or locally recurrent hormone receptor-positive (HR+)/HER2-negative breast cancer, a combination of abemaciclib (a CDK4/6 inhibitor), avutometinib, and fulvestrant (an estrogen receptor degrader) is under investigation.[8] Preclinical data also showed synergistic effects with eribulin in triple-negative breast cancer (TNBC) cell lines.[5]
• Pediatric Solid Tumors: Avutometinib is being evaluated for pediatric patients with refractory or recurrent solid tumors that harbor activating MAPK pathway alterations.[8]
• Glioblastoma: A study aims to identify appropriate treatment concentrations of defactinib or avutometinib for patients with glioblastoma.[8]
• Endometrial Cancer (KRAS-mutant): The FRAME study was expanded to include a cohort for patients with KRAS-mutant endometrial cancer.[16]

F. Detailed Review of Clinical Trial NCT03875820 (FRAME Study)

The clinical trial NCT03875820, known as the FRAME study, has played a significant role in the early clinical development of avutometinib in combination with defactinib.

• Official Title: While not explicitly stated in full in the documents, based on its description as an investigator-initiated Phase 1/2 study evaluating VS-6766 (avutometinib/RO5126766) in combination with defactinib (VS-6063) in patients with KRAS mutant tumors [16], and the user query's reference to it as a "Phase I Trial of VS-6063 and RO5126766," a likely title would be similar to "A Phase 1/2 Study of Avutometinib (VS-6766/RO5126766) in Combination with Defactinib (VS-6063) in Patients with Advanced Solid Tumors, Including Those with KRAS Mutations."
• Status: The trial is ongoing, with significant data having been presented at various scientific meetings.[16] Data from the FRAME study, alongside the RAMP 201 trial, supported the FDA's accelerated approval of the avutometinib and defactinib combination for LGSOC.[12]
• Study Type: Investigator-initiated trial.[16]
• Phase: Phase 1/2.[16]
• Sponsor/Collaborators: Being investigator-initiated, academic institutions such as The Institute of Cancer Research and The Royal Marsden have been involved in presenting data.[16] Verastem Oncology, as the developer of avutometinib and defactinib, supports and collaborates on such trials.
• Purpose: The primary objectives were to evaluate the safety, tolerability, and preliminary efficacy of avutometinib in combination with defactinib. The study enrolled patients with various advanced solid tumors, with a particular focus on those harboring KRAS mutations. Initial cohorts included LGSOC, KRAS-mutant NSCLC, and CRC.[16] The study was later expanded to include cohorts for pancreatic cancer and KRAS-mutant endometrial cancer.[16]
• Key Eligibility Criteria (General Inferences): Typically for such early-phase trials, eligibility would include adult patients with advanced or metastatic solid tumors who have progressed on prior standard therapies, possess measurable disease, have adequate organ function, and maintain a reasonable ECOG performance status (e.g., 0-1). Specific cohorts were defined by tumor type and/or KRAS mutation status.
• Arms and Interventions: The core intervention was the combination of avutometinib (VS-6766) and defactinib (VS-6063). The Phase 1 portion likely involved dose escalation to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by expansion cohorts at the selected dose.
• Outcome Measures (Typical for Phase 1/2):
• Primary (Phase 1): MTD, incidence of dose-limiting toxicities (DLTs), overall safety and tolerability.
• Primary (Phase 2): ORR.
• Secondary: DOR, PFS, DCR, pharmacokinetic parameters, and further assessment of the safety profile.
• Key Efficacy and Safety Results (LGSOC cohort as a primary example):
• In patients with recurrent LGSOC, the combination demonstrated an ORR of 42% (11/26 patients).[17] A separate report indicated an ORR of 56% in a KRAS-G12 mutant LGSOC cohort from FRAME.[16]
• The mDOR was reported as 26.9 months (95% CI: 8.5-47.3 months).[17]
• The mPFS was 20.0 months (95% CI: 11.1-31.2 months).[17]
• The safety profile of the combination was generally considered favorable and well-tolerated.[12]
• Published Data and Clinical Significance: Data from the FRAME study have been presented at major oncology conferences, including ESMO, AACR, and the RAS-Targeted Drug Development Summit.[9] The encouraging results, especially in LGSOC, led to the FDA granting Breakthrough Therapy Designation for the avutometinib plus defactinib combination.[4] Crucially, FRAME provided essential early proof-of-concept and the foundational rationale for initiating the subsequent Phase 2 registration-directed RAMP 201 trial [12], and its data contributed to the eventual accelerated FDA approval of the combination for KRAS-mutated LGSOC.[12]

The FRAME study (NCT03875820) serves as a compelling example of the successful and efficient translation of a strong preclinical rationale—the observed synergy of combined RAF/MEK and FAK inhibition—into clinically meaningful outcomes within an early-phase clinical trial. This success significantly de-risked and accelerated the subsequent stages of the development program for avutometinib plus defactinib. Preclinical investigations had pointed towards synergistic anti-tumor activity when RAF/MEK inhibitors were combined with FAK inhibitors, partly by overcoming FAK-mediated adaptive resistance.[5] The FRAME study was designed to test this hypothesis in human subjects across a variety of tumor types, including LGSOC.[16] The study yielded encouraging efficacy signals, particularly in LGSOC, with ORRs in the range of 42%-56% and notable durability of response (mDOR ~27 months) and progression-free survival (mPFS ~20 months).[16] These positive early clinical data were pivotal, leading to the FDA granting Breakthrough Therapy Designation [17] and directly informing the design and initiation of the registrational RAMP 201 trial.[17] Ultimately, these efforts contributed to the accelerated approval of the combination [12], illustrating a streamlined and successful early development pathway driven by strong science and early clinical validation.

V. Safety and Tolerability Profile

A. Comprehensive Overview of Adverse Events (AEs) from Avutometinib +/- Defactinib

The combination of avutometinib and defactinib, as evaluated primarily in the RAMP 201 trial for LGSOC, was reported to be generally well-tolerated.12 No new safety signals were identified during the course of these studies.12

The most common treatment-related adverse events (TRAEs) reported for the combination (typically defined as occurring in ≥20% or ≥25% of patients, with specific thresholds varying by report) include 11:

• Gastrointestinal: Nausea (67.0% any grade, 2.6% Grade 3+), Diarrhea (58.3% any grade, 7.8% Grade 3+), Vomiting.
• Musculoskeletal/Biochemical: Increased blood creatine phosphokinase (CPK) (60.0% any grade, 24.3% Grade 3+), Musculoskeletal pain.
• General: Fatigue, Edema.
• Hepatic: Increased aspartate aminotransferase (AST), Increased alanine aminotransferase (ALT), Increased blood bilirubin.
• Dermatological: Rash.
• Hematological: Decreased hemoglobin.

Understanding these common AEs is essential for patient management, allowing for appropriate monitoring, prophylactic measures, and symptomatic treatment. The incidence of Grade 3 or higher events highlights the more serious toxicities that require particular attention and potentially intervention.

B. Management of Key Toxicities (Warnings and Precautions from Product Labeling)

The prescribing information for AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) includes specific warnings and precautions regarding several key toxicities that necessitate careful monitoring and management [25]:

• Ocular Toxicities: Ocular adverse reactions are common, occurring in 68% of patients with recurrent LGSOC treated with the combination in RAMP-201.[28] These can include visual impairment (38%), dry eye, orbital/periorbital edema, and vitreous floaters. More serious vitreoretinal disorders occurred in 26% of patients, including retinal detachment (9%) and, rarely, retinal vein occlusion (0.7%). The median time to onset for symptomatic ocular AEs was 5 days, while for asymptomatic events it was 112 days; for retinal detachment, the median onset was 27 days. Management involves referring patients to an eye care professional for a comprehensive ophthalmic examination at baseline, prior to Cycle 2, every three cycles thereafter, and as clinically indicated. Prompt referral is needed for any new or worsening ocular symptoms. Depending on the severity and persistence of ocular AEs, treatment may need to be withheld, the dose reduced, or permanently discontinued.[25]
• Serious Skin Toxicities: Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARs), have been observed. Adherence to recommendations for concomitant medications (e.g., avoiding photosensitizing agents) is important. Skin toxicities should be monitored, and treatment interrupted, reduced, or permanently discontinued based on severity, tolerability, and duration.[25]
• Hepatotoxicity: Liver function tests (LFTs) should be monitored prior to each cycle, on day 15 of the first four cycles, and as clinically indicated. Dose adjustments (withholding, reduction, or discontinuation) are based on the severity and persistence of any abnormalities.[25]
• Rhabdomyolysis: Creatine phosphokinase (CPK) levels should be monitored prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If CPK levels are elevated, patients should be evaluated for rhabdomyolysis or other causes. Treatment modifications are based on the severity and duration of the adverse reaction.[11]
• Embryo-Fetal Toxicity: Avutometinib and defactinib can cause fetal harm. Patients of reproductive potential should be advised of this risk and counseled to use effective contraception during treatment and for a specified period after the last dose.[25]

These specific warnings underscore the AEs that require proactive and structured management strategies to ensure patient safety during treatment.

C. Dose Modifications and Discontinuation Rates

The tolerability of a regimen is also reflected in the rates of dose modifications and treatment discontinuations due to adverse events.

• RAMP 201 (Avutometinib + Defactinib in LGSOC):
• Approximately 10% of patients discontinued treatment due to AEs.[11]
• Regarding ocular AEs, 13% of patients experienced an event that led to dose interruption of the combination, and one patient required a dose reduction due to an ocular AE.[28]
• One report, referring to the combination arm in Part A of RAMP 201, mentioned dose reductions occurred in 17% of patients, and 12% of patients discontinued either avutometinib or defactinib due to AEs.[17]
• RAMP 201 Part D (Dose Optimization): An important finding from Part D of the RAMP 201 study, which explored dose optimization, was that a lower dose of avutometinib (1.6 mg twice weekly) resulted in worse outcomes and lower efficacy compared to the standard 3.2 mg dose. This led to the conclusion that the 1.6 mg dose would not be pursued as a starting dose, emphasizing the importance of initiating treatment at the standard prescribed dose for optimal efficacy.[21]

Discontinuation rates and the necessity for dose modifications serve as crucial indicators of the overall manageability and tolerability of the avutometinib-defactinib regimen in clinical practice.

Table V.1: Common Treatment-Related Adverse Events (TRAEs) (≥20% any grade) with Avutometinib + Defactinib in LGSOC (RAMP 201)

Adverse Event	Any Grade (%)	Grade 3+ (%)	Source Document(s)
Nausea	67.0	2.6	11
Increased Creatine Phosphokinase	60.0	24.3	11
Diarrhea	58.3	7.8	11
Fatigue	≥25	N/A	13
Increased Aspartate Aminotransferase	≥25	N/A	13
Rash	≥25	N/A	13
Musculoskeletal Pain	≥25	N/A	13
Edema	≥25	N/A	13
Decreased Hemoglobin	≥25	N/A	13
Increased Alanine Aminotransferase	≥25	N/A	13
Vomiting	≥25	N/A	13
Increased Blood Bilirubin	≥25	N/A	13
Visual Impairment	38 (ocular AEs overall 68%)	N/A	13

[11]

The safety profile of avutometinib, whether administered alone or in combination with defactinib, is characterized by a set of commonly occurring adverse events that are generally manageable, alongside specific, potentially serious toxicities that demand vigilant baseline screening, consistent monitoring, and clearly defined management protocols. While common AEs such as nausea, diarrhea, and fatigue are frequently reported, they are predominantly of low grade.[11] However, certain toxicities, like increased CPK levels, can manifest as high-grade events (24.3% Grade 3+ in RAMP 201 [11]), which directly relates to the identified risk of rhabdomyolysis.[25] Ocular toxicities are also notably prevalent, occurring in 68% of patients in one report [28], and can encompass serious events such as retinal detachment (9% incidence in the same report [28]). Consequently, the FDA-approved labeling for the combination includes explicit warnings for these specific toxicities and mandates structured monitoring protocols, including regular ophthalmologic examinations.[25] This implies that while the therapeutic regimen offers significant efficacy, its safe administration is contingent upon a proactive and systematic approach to safety management to mitigate potential risks.

Despite the range of reported adverse events, some of which have a high incidence (e.g., nausea 67%, CPK increase 60%, overall ocular AEs 68% [11]), the rate of treatment discontinuation due to these AEs is relatively modest, reported at 10-12% in the RAMP 201 trial for the combination therapy.[11] This apparent discrepancy suggests that a majority of the observed toxicities are of low severity or can be effectively managed through measures such as dose interruptions, dose reductions (which occurred in 17% of patients in one cohort report [17]), or other appropriate supportive care. The ability for most patients to continue therapy, despite experiencing AEs, is a positive indicator of the regimen's overall clinical utility and manageability, allowing patients the opportunity to derive sustained therapeutic benefit.

VI. Regulatory Status and Future Perspectives

A. U.S. FDA Regulatory Milestones

Avutometinib, in combination with defactinib, has achieved significant regulatory milestones in the United States, reflecting its potential to address unmet medical needs:

• Accelerated Approval: On May 8, 2025, the FDA granted accelerated approval to the combination of avutometinib and defactinib (marketed as Avmapki Fakzynja Co-pack by Verastem, Inc.) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received at least one prior systemic therapy.[12]
• This approval was based on the efficacy data, specifically overall response rate (ORR) and duration of response (DOR), from the RAMP-201 (NCT04625270) clinical trial.[13]
• As is standard for accelerated approvals, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.[28] The RAMP 301 trial is designated as this confirmatory study.[17]
• Breakthrough Therapy Designation: The combination of avutometinib and defactinib received Breakthrough Therapy Designation from the FDA for the treatment of recurrent LGSOC.[4]
• Orphan Drug Designation: This designation was granted by the FDA for avutometinib in combination with defactinib for LGSOC.[13] Avutometinib monotherapy also received Orphan Drug Designation for LGSOC.[19]
• Priority Review: The New Drug Application (NDA) for the combination in LGSOC was granted Priority Review by the FDA.[13]
• Fast Track Designation: The combination of avutometinib and sotorasib for the treatment of KRAS G12C-mutant NSCLC received Fast Track Designation.[23]
• Review Process Enhancements: The review of the NDA for LGSOC utilized programs such as the Real-Time Oncology Review (RTOR) pilot program and the Assessment Aid, designed to streamline and facilitate the FDA's assessment process.[13]

These various designations and expedited review pathways underscore the FDA's recognition of the significant unmet medical need in LGSOC and the promising nature of the clinical data generated by avutometinib in combination with defactinib.

B. European Medicines Agency (EMA) Interactions and Status

Information regarding specific regulatory interactions with the European Medicines Agency (EMA) for marketing authorisation of avutometinib is limited in the provided documents.

• Clinical trial activity involving avutometinib is ongoing in Europe, as evidenced by the RAMP 203 trial (evaluating avutometinib plus sotorasib in NSCLC) having a EudraCT number (2022-004111-83), which is required for trials conducted in the European Union.[22] The same document also notes that sotorasib, one of the combination partners, is approved by the EMA.[22]
• A document dated March 2025 (prior to the May 2025 FDA approval) stated that avutometinib and defactinib were investigational drugs not yet approved by the FDA or any other regulatory health authority, implying no EMA approval at that time.[4]
• No specific information regarding a marketing authorisation application submission to the EMA, a Committee for Medicinal Products for Human Use (CHMP) opinion, or EMA approval for avutometinib was found in the provided materials.[23]

While clinical development extends to regions under EMA jurisdiction, the current regulatory status with the EMA for avutometinib specifically is not detailed beyond authorizations for clinical trials.

C. Ongoing Confirmatory Trials and Future Development Plans

The regulatory journey for avutometinib is ongoing, with further validation and expansion of its indications being key objectives.

• RAMP 301 (ENGOT-ov84/GOG-3086): This is a Phase 3 confirmatory clinical trial designed to verify the clinical benefit of avutometinib plus defactinib in patients with recurrent LGSOC.[28] The design of this trial has been presented [17], and its successful completion and positive outcome will be crucial for converting the current accelerated approval in the U.S. to full approval.
• Continued Development in Other Cancers: Verastem Oncology is pursuing a broad development program for avutometinib in other malignancies, including NSCLC (e.g., RAMP 203 with sotorasib, RAMP 204 with adagrasib) and pancreatic cancer (RAMP 205 with defactinib and chemotherapy), as well as other RAS pathway-driven cancers.[8]
• NCCN Guidelines: There are plans to submit the primary analysis from the RAMP 201 trial for consideration by the National Comprehensive Cancer Network (NCCN) for inclusion in its clinical practice guidelines.[20]

This ongoing and planned research indicates a long-term strategy to establish avutometinib as a significant therapy across multiple oncological settings.

D. Potential Impact and Unmet Needs Addressed

The approval and ongoing development of avutometinib, particularly in combination with defactinib, represent a significant advancement for patients with certain difficult-to-treat cancers.

• First Approved Therapy for KRAS-Mutant LGSOC: The combination of avutometinib and defactinib is the first and currently only therapy specifically approved by the FDA for adult patients with KRAS-mutated recurrent LGSOC.[29] This addresses a critical unmet medical need, as LGSOC is a rare cancer with historically limited effective treatment options.[18]
• Improved Efficacy in LGSOC: Prior to this approval, existing treatments for LGSOC typically yielded ORRs in the range of 0% to 26%.[18] The 44% ORR observed with avutometinib plus defactinib in the KRAS-mutant LGSOC population in the RAMP 201 trial signifies a substantial improvement in efficacy for these patients.

The accelerated approval of avutometinib plus defactinib, based on Phase 2 data from the RAMP 201 trial for KRAS-mutant LGSOC, exemplifies the FDA's commitment to expediting access to promising therapies for rare cancers and underserved patient populations. LGSOC is indeed a rare malignancy with few effective treatments.[18] The FDA recognized the potential of this combination by granting Breakthrough Therapy, Orphan Drug, and Priority Review designations.[13] The accelerated approval pathway, which allows for earlier patient access based on surrogate endpoints like ORR and DOR from a Phase 2 trial [13], is a critical mechanism for such situations. However, this pathway inherently places significant emphasis on the successful completion and positive outcome of the subsequent confirmatory Phase 3 trial, RAMP 301.[17] The continued availability of the drug under this approval is contingent upon demonstrating clinical benefit in this larger, more definitive study.[28] Therefore, the RAMP 301 trial assumes paramount importance for solidifying the role of avutometinib plus defactinib in LGSOC and maintaining its regulatory approval.

The extensive and diverse clinical development program for avutometinib, which encompasses investigations in multiple tumor types and various combination strategies, suggests the potential for this agent to become a "pipeline-in-a-pill." Avutometinib is currently being evaluated in a wide array of cancers, including LGSOC, NSCLC, pancreatic cancer, colorectal cancer, melanoma, thyroid cancer, endometrial cancer, breast cancer, and pediatric tumors.[8] Furthermore, it is being tested in combination with FAK inhibitors, KRAS G12C inhibitors, standard chemotherapy regimens, endocrine therapies, and anti-EGFR therapies.[8] If these diverse investigations yield successful outcomes and lead to further regulatory approvals, avutometinib could establish its utility across numerous oncogenic contexts that are driven by alterations in the targeted MAPK pathway. This strategy effectively maximizes the therapeutic potential of a single molecular entity by systematically exploring its efficacy in various settings where its mechanism of action is relevant.

VII. Conclusion

A. Summary of Avutometinib's Profile and Therapeutic Potential

Avutometinib has emerged as a novel, orally bioavailable, dual RAF/MEK inhibitor with a unique "RAF/MEK clamp" mechanism of action. This distinct mechanism, which aims to provide more complete and sustained inhibition of the MAPK pathway by preventing feedback reactivation of MEK, offers potential advantages over conventional MEK inhibitors. Significant clinical efficacy has been demonstrated, most notably with the combination of avutometinib and the FAK inhibitor defactinib in patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), leading to its first FDA accelerated approval. This approval addresses a significant unmet medical need in this rare cancer subtype. Beyond LGSOC, avutometinib is showing promise and is under active investigation in a broad range of other RAS/MAPK pathway-driven cancers, including non-small cell lung cancer and pancreatic cancer, often as part of rational combination therapies.

B. Key Considerations for Clinical Application and Further Research

The successful integration of avutometinib into clinical practice and its continued development hinge on several key considerations:

• Biomarker-Driven Patient Selection: The importance of biomarker testing, particularly for KRAS mutations in LGSOC, is paramount for identifying patients most likely to benefit. Further research into other potential biomarkers, such as EMT status in NSCLC, may refine patient selection in other indications.
• Management of Toxicities: Proactive and vigilant management of characteristic adverse events associated with avutometinib-based regimens is crucial. This includes careful monitoring for and management of ocular toxicities, CPK elevations (and risk of rhabdomyolysis), dermatologic reactions, and hepatotoxicity, often requiring specialized care and adherence to management guidelines.
• Confirmatory Clinical Data: The outcomes of ongoing and planned Phase 3 confirmatory trials, such as RAMP 301 for LGSOC, will be critical for converting accelerated approvals to full approvals and definitively establishing the risk-benefit profile.
• Optimization of Combination Strategies: Continued research is needed to determine the optimal combination partners, dosing schedules, and sequences of therapy for avutometinib in various tumor types and molecular contexts.
• Understanding Resistance Mechanisms: As with all targeted therapies, investigating and understanding mechanisms of acquired resistance to avutometinib-based treatments will be essential for developing strategies to overcome or delay resistance and improve long-term outcomes.

Avutometinib represents a significant and promising advancement in the field of targeted cancer therapy, particularly for malignancies driven by the RAS/MAPK pathway. Its unique "RAF/MEK clamp" mechanism and the initial clinical success in LGSOC are noteworthy achievements. However, the broader impact of avutometinib on the oncology landscape will ultimately depend on the successful outcomes of its extensive ongoing clinical trial program across diverse indications, the ability to successfully navigate confirmatory studies for its current approval, and the effective clinical management of its distinct safety profile. This includes a particular emphasis on specialized monitoring, such as regular ophthalmologic assessments, to ensure patient safety. The journey of avutometinib from a novel chemical entity to a potentially widely used anticancer agent is at a critical juncture, characterized by substantial therapeutic opportunity balanced by the imperative for further rigorous validation and careful clinical implementation.

Works cited

1. Avutometinib | C21H18FN5O5S | CID 16719221 - PubChem, accessed May 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/avutometinib
2. Avutometinib | CAS#946128-88-7 | Raf/MEK Inhibitor | MedKoo ..., accessed May 30, 2025, https://www.medkoo.com/products/5804
3. avutometinib | Ligand page | IUPHAR/BPS Guide to MALARIA PHARMACOLOGY, accessed May 30, 2025, https://www.guidetomalariapharmacology.org/GRAC/LigandDisplayForward?ligandId=11867
4. Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (ENGOT-ov60/GOG-3052/RAMP 201): Dose Intensity and Subgroup Analysis - Verastem Oncology, accessed May 30, 2025, https://www.verastem.com/wp-content/uploads/2025/03/RAMP-201-Oral-Presentation-SGO-2025_03.17.25f.pdf
5. Avutometinib supplier | CAS 946128-88-7 | Focus Biomolecules, accessed May 30, 2025, https://focusbiomolecules.com/avutometinib-dual-mek-raf-inhibitor/
6. BRAF, a tumor-agnostic drug target with lineage-specific dependencies - PMC, accessed May 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11857949/
7. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review - PMC - PubMed Central, accessed May 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9989806/
8. Clinical Trials Using Avutometinib - NCI, accessed May 30, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/avutometinib?pn=1
9. Corporate Presentation - Verastem Oncology, accessed May 30, 2025, https://www.verastem.com/wp-content/uploads/2022/12/Verastem_Corporate_Presentation_11-21-22.pdf
10. Avutometinib Active Not Recruiting Phase 1 / 2 Trials for Malignant Neoplasm of Lung / Metastatic Cancer / KRAS Activating Mutation / Cancer / Non-Small Cell Lung Cancer (NSCLC) / Advanced Malignant Neoplasm Treatment - DrugBank, accessed May 30, 2025, https://go.drugbank.com/drugs/DB15254/clinical_trials?conditions=DBCOND0033490%2CDBCOND0020966%2CDBCOND0088037%2CDBCOND0054441%2CDBCOND0028461%2CDBCOND0034130&phase=1%2C2&purpose=treatment&status=active_not_recruiting
11. Avutometinib With Defactinib Accepted for Review by FDA in Recurrent LGSOC, accessed May 30, 2025, https://www.cancernetwork.com/view/avutometinib-with-defactinib-accepted-for-review-by-fda-in-recurrent-lgsoc
12. Avutometinib Plus Defactinib Gains FDA Approval in KRAS+ ..., accessed May 30, 2025, https://www.targetedonc.com/view/avutometinib-plus-defactinib-gains-fda-approval-in-kras-ovarian-cancer
13. FDA grants accelerated approval to the combination of avutometinib ..., accessed May 30, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low
14. Epithelial-mesenchymal transition status is a remarkable biomarker ..., accessed May 30, 2025, https://pubmed.ncbi.nlm.nih.gov/38822146/
15. Compound: AVUTOMETINIB (CHEMBL3264002) - ChEMBL, accessed May 30, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3264002
16. Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit, accessed May 30, 2025, https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-updated-phase-12-frame/
17. www.verastem.com, accessed May 30, 2025, https://www.verastem.com/wp-content/uploads/2025/01/Grisham_et_al_SGO_2024_RAMP_301_TiP.pdf
18. Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC, accessed May 30, 2025, https://www.onclive.com/view/avutometinib-plus-defactinib-shows-high-response-rates-in-heavily-treated-lgsoc
19. Avutometinib/Defactinib Earns FDA Accelerated Approval for KRAS+ LGSOC - Oncology Nursing News, accessed May 30, 2025, https://www.oncnursingnews.com/view/avutometinib-defactinib-granted-accelerated-approval-for-kras-lgsoc
20. A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation - Cancer Trial Results, accessed May 30, 2025, https://clin.larvol.com/trial-detail/NCT04625270
21. RAMP 201 Shows “Impressive” Data in KRAS+ Low-Grade Serous ..., accessed May 30, 2025, https://www.cancernetwork.com/view/ramp-201-shows-impressive-data-in-kras-low-grade-serous-ovarian-cancer
22. RAMP 203 - NHS Health Research Authority, accessed May 30, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ramp-203/
23. Regulatory News - MedNess, accessed May 30, 2025, https://medness.org/section/onconews/regulatory-news/
24. Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review, accessed May 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12037499/
25. Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates, accessed May 30, 2025, https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-reports-first-quarter-2025-financial-results/
26. News - avutometinib (VS-6766) - LARVOL VERI, accessed May 30, 2025, https://veri.larvol.com/news/vs-6766/drug
27. ATR/PARP Inhibition May Overcome PARP Resistance in High-Grade Serous Ovarian Cancer - Targeted Oncology, accessed May 30, 2025, https://www.targetedonc.com/view/atr-parp-inhibition-may-overcome-parp-resistance-in-high-grade-serous-ovarian-cancer
28. Label: AVMAPKI FAKZYNJA CO-PACK- avutometinib potassium and defactinib hydrochloride kit - DailyMed, accessed May 30, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65889527-1406-45df-8a85-e2690dcf427d&version=2
29. Pharma News | Verastem, Thermosome, Capsida - DelveInsight, accessed May 30, 2025, https://www.delveinsight.com/blog/pharma-news-for-verastem-thermosome-capsida
30. Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - Pharmacy Times, accessed May 30, 2025, https://www.pharmacytimes.com/view/avutometinib-plus-defactinib-moves-one-step-closer-to-approval-for-treatment-of-ovarian-cancer
31. EU Panel Recommends Capmatinib for METex14-Altered Advanced NSCLC - OncLive, accessed May 30, 2025, https://www.onclive.com/view/eu-panel-recommends-capmatinib-for-metex14-altered-advanced-nsclc